JP2019513370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513370A5 JP2019513370A5 JP2018551953A JP2018551953A JP2019513370A5 JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5 JP 2018551953 A JP2018551953 A JP 2018551953A JP 2018551953 A JP2018551953 A JP 2018551953A JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- amino acid
- acid sequence
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317068P | 2016-04-01 | 2016-04-01 | |
| US62/317,068 | 2016-04-01 | ||
| PCT/US2017/025573 WO2017173384A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152515A Division JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513370A JP2019513370A (ja) | 2019-05-30 |
| JP2019513370A5 true JP2019513370A5 (cg-RX-API-DMAC7.html) | 2019-10-24 |
Family
ID=59960746
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551953A Pending JP2019513370A (ja) | 2016-04-01 | 2017-03-31 | キメラ受容体及びその使用方法 |
| JP2020152515A Active JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
| JP2022136417A Active JP7451627B2 (ja) | 2016-04-01 | 2022-08-30 | キメラ受容体及びその使用方法 |
| JP2024033511A Active JP7673272B2 (ja) | 2016-04-01 | 2024-03-06 | キメラ受容体及びその使用方法 |
| JP2025071243A Pending JP2025111619A (ja) | 2016-04-01 | 2025-04-23 | キメラ受容体及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152515A Active JP7134204B2 (ja) | 2016-04-01 | 2020-09-11 | キメラ受容体及びその使用方法 |
| JP2022136417A Active JP7451627B2 (ja) | 2016-04-01 | 2022-08-30 | キメラ受容体及びその使用方法 |
| JP2024033511A Active JP7673272B2 (ja) | 2016-04-01 | 2024-03-06 | キメラ受容体及びその使用方法 |
| JP2025071243A Pending JP2025111619A (ja) | 2016-04-01 | 2025-04-23 | キメラ受容体及びその使用方法 |
Country Status (33)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AU2017242893A1 (en) | 2016-03-31 | 2018-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
| KR102359735B1 (ko) | 2016-03-31 | 2022-02-08 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| CN109069482B (zh) | 2016-04-01 | 2022-04-05 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物 |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR102427334B1 (ko) * | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2018215316A1 (en) | 2017-05-22 | 2018-11-29 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| BR112019024195A2 (pt) | 2017-05-22 | 2020-06-23 | Janssen Pharmaceuticals, Inc. | Composto e composição farmacêutica de derivados de indolina substituídos como inibidores da replicação viral da dengue |
| US11390655B2 (en) * | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| AU2019318135A1 (en) * | 2018-08-10 | 2021-03-04 | Sangamo Therapeutics France | New car constructs comprising TNFR2 domains |
| KR20210089179A (ko) * | 2018-10-26 | 2021-07-15 | 카파 테라퓨틱스 리미티드 | Cll1을 표적으로 하는 항체 및 이의 응용 |
| CN113543799B (zh) | 2019-03-01 | 2024-08-02 | 艾洛基治疗公司 | 靶向dll3的嵌合抗原受体和结合剂 |
| JP2022531439A (ja) * | 2019-05-07 | 2022-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ヒンジドメインを介したポリペプチド及びキメラ抗原受容体の増強 |
| BR112021026832A2 (pt) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| JP7776414B2 (ja) * | 2019-09-13 | 2025-11-26 | メモリアル スローン ケタリング キャンサー センター | Ｃｄ３７１を標的にする抗原認識受容体およびその使用 |
| CN113980134B (zh) | 2020-12-11 | 2022-05-31 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113416713A (zh) * | 2021-05-11 | 2021-09-21 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种重组腺病毒的构建及其应用 |
| CN115521917A (zh) * | 2021-06-25 | 2022-12-27 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| WO2023147331A1 (en) | 2022-01-26 | 2023-08-03 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targetted antigen |
| TW202340457A (zh) * | 2022-02-28 | 2023-10-16 | 美商凱特製藥公司 | 同種異體治療細胞 |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| WO2024186695A2 (en) * | 2023-03-03 | 2024-09-12 | Trustees Of Boston University | Immune cell fusion (icf) and uses thereof |
| TW202442683A (zh) * | 2023-04-18 | 2024-11-01 | 德克薩斯大學系統董事會 | Ｂｃｍａ嵌合抗原受體及其用途 |
| WO2025194098A1 (en) | 2024-03-14 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same |
| WO2025231376A1 (en) * | 2024-05-03 | 2025-11-06 | Kite Pharma, Inc. | Chimeric receptors binding to cll-1 and methods of use thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| NZ543635A (en) | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DE112005002126B4 (de) | 2004-09-03 | 2018-05-09 | General Motors Corp. | Ausrichtungssystem und -verfahren für sich wiederholende und nicht wiederholende Einheiten in einem Brennstoffzellenstapel |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| AU2010320547B2 (en) | 2009-11-17 | 2016-06-09 | Basf Plant Science Company Gmbh | Plants with increased yield |
| EP2566886A1 (en) | 2010-05-05 | 2013-03-13 | Addex Pharma SA | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PT3012268T (pt) | 2010-09-08 | 2018-01-31 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Recetores de antigénio quimérico com uma região de charneira otimizada |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| WO2012163805A1 (en) | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| AU2012308205A1 (en) | 2011-09-16 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP2836239A1 (en) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| KR102417657B1 (ko) | 2013-02-06 | 2022-07-07 | 안트로제네시스 코포레이션 | 개선된 특이성을 갖는 변경된 t 림프구 |
| PL3300745T3 (pl) | 2013-02-15 | 2020-03-31 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
| US9629877B2 (en) | 2013-05-14 | 2017-04-25 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015077789A2 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
| US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| CN114395530A (zh) | 2014-02-04 | 2022-04-26 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| EP3171882A1 (en) * | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using a cll-1 chimeric antigen receptor |
| CA2956002C (en) | 2014-07-24 | 2023-06-27 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| CN107002084B (zh) | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| AU2015360845B2 (en) | 2014-12-12 | 2020-11-26 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| SG10201912819XA (en) | 2015-04-13 | 2020-02-27 | Pfizer | Therapeutic antibodies and their uses |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| US20190183931A1 (en) | 2016-04-01 | 2019-06-20 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
-
2017
- 2017-03-31 PE PE2018001934A patent/PE20190356A1/es unknown
- 2017-03-31 MA MA43603A patent/MA43603A1/fr unknown
- 2017-03-31 CR CR20210084A patent/CR20210084A/es unknown
- 2017-03-31 AR ARP170100821A patent/AR108066A1/es unknown
- 2017-03-31 PE PE2020001605A patent/PE20211418A1/es unknown
- 2017-03-31 ES ES17776859T patent/ES2930058T3/es active Active
- 2017-03-31 KR KR1020257007542A patent/KR20250039495A/ko active Pending
- 2017-03-31 UA UAA201909739A patent/UA128781C2/uk unknown
- 2017-03-31 CN CN202110248927.7A patent/CN113150170B/zh active Active
- 2017-03-31 UA UAA201809953A patent/UA123276C2/uk unknown
- 2017-03-31 LT LTEPPCT/US2017/025573T patent/LT3436030T/lt unknown
- 2017-03-31 KR KR1020247037911A patent/KR102779944B1/ko active Active
- 2017-03-31 BR BR112018070260A patent/BR112018070260A2/pt active Search and Examination
- 2017-03-31 KR KR1020187031572A patent/KR102120815B1/ko active Active
- 2017-03-31 EP EP17776859.5A patent/EP3436030B1/en active Active
- 2017-03-31 SI SI201731265T patent/SI3436030T1/sl unknown
- 2017-03-31 JP JP2018551953A patent/JP2019513370A/ja active Pending
- 2017-03-31 SG SG10201912519VA patent/SG10201912519VA/en unknown
- 2017-03-31 CR CR20180480A patent/CR20180480A/es unknown
- 2017-03-31 PL PL17776859.5T patent/PL3436030T3/pl unknown
- 2017-03-31 CN CN201780022074.7A patent/CN109641008B/zh active Active
- 2017-03-31 US US15/476,699 patent/US10597456B2/en active Active
- 2017-03-31 IL IL316403A patent/IL316403A/en unknown
- 2017-03-31 CA CA3019650A patent/CA3019650C/en active Active
- 2017-03-31 AU AU2017240788A patent/AU2017240788B2/en active Active
- 2017-03-31 CN CN202511224360.4A patent/CN121108368A/zh active Pending
- 2017-03-31 EP EP22191077.1A patent/EP4180449A1/en active Pending
- 2017-03-31 DK DK17776859.5T patent/DK3436030T3/da active
- 2017-03-31 HU HUE17776859A patent/HUE060645T2/hu unknown
- 2017-03-31 SM SM20220444T patent/SMT202200444T1/it unknown
- 2017-03-31 HR HRP20221348TT patent/HRP20221348T1/hr unknown
- 2017-03-31 PT PT177768595T patent/PT3436030T/pt unknown
- 2017-03-31 CA CA3177398A patent/CA3177398A1/en active Pending
- 2017-03-31 MX MX2018012019A patent/MX2018012019A/es unknown
- 2017-03-31 KR KR1020227039755A patent/KR102608405B1/ko active Active
- 2017-03-31 RS RS20221024A patent/RS63735B1/sr unknown
- 2017-03-31 MY MYPI2018703599A patent/MY197669A/en unknown
- 2017-03-31 KR KR1020207015941A patent/KR20200068750A/ko not_active Ceased
- 2017-03-31 KR KR1020237040899A patent/KR102731644B1/ko active Active
- 2017-03-31 PE PE2019002307A patent/PE20200400A1/es unknown
- 2017-03-31 KR KR1020217021089A patent/KR20210089262A/ko not_active Ceased
- 2017-03-31 WO PCT/US2017/025573 patent/WO2017173384A1/en not_active Ceased
- 2017-03-31 IL IL262041A patent/IL262041B2/en unknown
- 2017-03-31 EA EA201891992A patent/EA201891992A1/ru unknown
- 2017-03-31 SG SG11201808595WA patent/SG11201808595WA/en unknown
- 2017-04-05 TW TW109107507A patent/TWI714470B/zh active
- 2017-04-05 TW TW106111224A patent/TW201803896A/zh unknown
- 2017-04-05 TW TW109145084A patent/TWI792123B/zh active
- 2017-04-05 TW TW112101087A patent/TWI855499B/zh active
-
2018
- 2018-10-01 MX MX2023002556A patent/MX2023002556A/es unknown
- 2018-10-01 PH PH12018502113A patent/PH12018502113A1/en unknown
- 2018-10-01 CO CONC2018/0010547A patent/CO2018010547A2/es unknown
- 2018-10-01 CL CL2018002797A patent/CL2018002797A1/es unknown
-
2019
- 2019-08-14 CL CL2019002310A patent/CL2019002310A1/es unknown
- 2019-10-21 US US16/658,480 patent/US20200115457A1/en not_active Abandoned
-
2020
- 2020-06-15 AU AU2020203990A patent/AU2020203990A1/en not_active Abandoned
- 2020-09-11 JP JP2020152515A patent/JP7134204B2/ja active Active
- 2020-10-15 CL CL2020002677A patent/CL2020002677A1/es unknown
-
2021
- 2021-06-30 CL CL2021001750A patent/CL2021001750A1/es unknown
-
2022
- 2022-07-08 CL CL2022001873A patent/CL2022001873A1/es unknown
- 2022-08-30 JP JP2022136417A patent/JP7451627B2/ja active Active
-
2023
- 2023-03-03 US US18/178,086 patent/US20230331855A1/en active Pending
- 2023-07-24 AU AU2023208077A patent/AU2023208077A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033511A patent/JP7673272B2/ja active Active
-
2025
- 2025-04-23 JP JP2025071243A patent/JP2025111619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513370A5 (cg-RX-API-DMAC7.html) | ||
| CN111018986B (zh) | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 | |
| AU2019243665B2 (en) | Multivalent antibody | |
| JP6588534B2 (ja) | 抗ｐｄ−１のモノクローナル抗体およびその獲得方法 | |
| JP2022550832A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| CA3116294C (en) | Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same | |
| WO2018108106A1 (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2020508655A5 (cg-RX-API-DMAC7.html) | ||
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2018532383A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536322A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522888A5 (cg-RX-API-DMAC7.html) | ||
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018528786A5 (cg-RX-API-DMAC7.html) | ||
| KR20230143177A (ko) | 신규한 항-cd24 항체 | |
| JP2024001073A5 (cg-RX-API-DMAC7.html) | ||
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| AU2020400801B2 (en) | Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JPWO2022111633A5 (cg-RX-API-DMAC7.html) | ||
| KR20210046725A (ko) | 신규 암 면역요법 항체 조성물 | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JPWO2019219064A5 (cg-RX-API-DMAC7.html) |